29 29.1 - Moved language to Sections 17.4.1 and 17.4.2. 20141218 1430 RB 2.1 8 15.4 16.1 20.2 STUDY ROAD MAP - To serve as a baseline measure, a new time point for the collection of peripheral blood for immunologic monitoring was added prior to non-mobilized leukapheresis. 15.2.2 15.3.3 19.4 - Two new, “Leukapheresis for Peripheral Blood Mononuclear Cells (PBMCs)”, sections were added to outline specific parameters for PBMC collection. The “ Procedure for PBSC Mobilization and Leukapheresis ” and “Procedure Leukapheresis” sections were re- named and amended to provide each institution the flexibility to follow their local standards and to provide guidelines for PBSC mobilization and apheresis duration. The “Leukapheresis and PBSC Mobilization” section was deleted since the content was already covered in other protocol sections. 2.1 8 10.2 15.2.3 15.3.4 - Language was added to clarify that focal boost radiotherapy for local control is allowed. Re-MATC H Protocol Page 6 of 106 Version: 20180628 Summary of Protocol Changes Version Date Sections Revised Purpose 19.5 - Language was amended for clarity and to correlate with minor changes to the manufacturing processes. Entire Document 30 30.1 - Reference to study -specific documents (Standard Operating Procedures, Batch Records, and Source Document Worksheets) was added throughout the entire protocol . A new “Ap pendices” section was added that lists each document number and title referenced in the narrative sections. 20150306 0715 RB 2.1 10.1 11.2 - Language was amended to clearly define subjects who have received and failed definitive standard radiotherapy. 19.4 - ‘Leukapheresis’ was replaced with ‘PBMCs’, ‘DMSO’ was replaced with ‘Cryoserv’, ‘production’ was replaced with ‘stimulation’, and ‘cell’ was replaced with ‘DC’ to more clearly outline the manufacturing process. ‘Ph’ was amended to “PH’. 8 15.3.1 - The instructions for peripheral blood stem cell administration were amended to allow each institution the flexibility to infuse the cells in accordance with local guidelines. 2.1 8 15.4 16.1 20.2 STUDY ROAD MAP - Select immune monitoring time points were amended to allow for flexibility in collection time. The requirement for bimonthly immune monitoring samples was revised to ‘if feasible’ to accommodate subjects who may not be seen at the main institution. 8 15.3.1 15.3.2 16.2 - The terms ‘up to’ were added to the acetaminophen and benadryl pre-medication language to allow for dosing flexibility, 20150622 0930 RB 8 15.3.1 15.3.2 - To provide institutions the flexibility to follow local guidelines, IV was added as a route of administration for Sargramostim and Filgrastim. 20.2 STUDY ROAD MAP - To enhance DC trafficking, Td booster will be administered to all subjects regardless of vaccination history.